e-med
[Top] [All Lists]

[e-med] DNDi reçois 6.5 million£ du guovernementanglais pour la recherche sur les maladies négligées

Encore une fois le gouvernement Britannique met en pratique ses discours
officiels en faveur de l'aide au développement de la Recherche et
Développement de nouvelles thérapies pour lutter contre les maladies 
négligées.

En effet, la Grande Bretagne vient d'allouer la somme de  9, 5 millions
d'Euros à la Fondation Drugs for Neglected Disease Initiative
(DNDi),  Fondation consacrée à la R&D de nouveaux médicaments pour lutter
contre les maladies les plus négligées, comme la trypanosomiase et la
maladie de Chagas.

La Fondation DNDi, créée par Médecin sans Frontières en 2003, est une
initiative qui a été soutenue dès 1997 par un Fonds de Solidarité
Prioritaire du Ministère Français des Affaires Etrangères (FSP97008500),
dont le budget était alloué pour établir les bases d'une politique de
développement pharmaceutique portant sur les maladies tropicales.
La Fondation DNDi a par la suite établi son siège à Genève en 2003, et a
été soutenu financièrement jusqu'à présent par MSF, dans l'attente d'un
relais par les gouvernements. Elle coordonne actuellement 20 projets à
plusieurs niveaux de développement pharmaceutique.

En dehors de MSF, 5 partenaires publiques se sont joints à la création de
la fondation DNDi: La Fondation Oswaldo Cruz, Brésil; Le Council of Medical
Research, Inde; le Medical Research Institute, Kenya; le Ministère de la
Santé de Malaisie; et l'Institut Pasteur, France.

La Grande Bretagne est le premier pays à apporter une contribution
financière à la Fondation DNDi.

Traduction partielle et commentaires
Pascal MILLET
Université Victor Segalen Bordeaux2
pascal.millet@u-bordeaux2.fr

***********************

UK government commits £6.5 million to DNDi's research for new medicines for 
neglected diseases
Geneva, March 9, 2005: The UK's Department of International Development 
(DFID) today granted £6.5 million (9.5 million Euros) to the Drugs for 
Neglected Diseases initiative (DNDi) for essential research and development 
of drugs for neglected diseases such as human African trypanosomiasis, 
leishmaniasis, Chagas disease, and malaria.
"We congratulate the UK government for this generous commitment to R&D that 
will make available safe, effective, practical-to-use, and affordable drugs 
so desperately needed by patients," remarked Dr. Bernard Pecoul, Executive 
Director of DNDi.  "This grant gives hope to millions of patients who 
unacceptably die or suffer from these diseases in the poorest regions of the 
world."

The grant, spread over three years, is critical support for DNDi to further 
develop its North and South public and private partnerships to address the 
significant drug development gap for neglected tropical diseases. With a 
current portfolio of 20 projects, DNDi aims to develop 6 to 8 new, improved, 
and field-relevant drugs by 2014, including two new malaria treatments that 
will be registered by the end of 2006.

Gareth Thomas, UK International Development Minister, said: "Forgotten and 
neglected diseases threaten up to half a billion people worldwide. 
Developing better and new treatments, and giving people the tools to tackle 
disease, is vital if we are to address the long-term health, not only of 
individuals, but of poor nations too. Funding initiatives such as these are 
key to our fight against poverty."

A massive governmental commitment is needed to address the urgent needs of 
patients suffering from these poverty-related diseases. While the 
establishment of product development partnerships (PDPs) like DNDi 
represents an important evolution for neglected diseases research, these 
PDPs have mainly been supported by philanthropic organizations until now. 
For instance, Médecins Sans Frontières (MSF), catalyzed the creation of DNDi 
with a 2003 commitment of 25 million Euros. To sustain the momentum slowly 
achieved in this field of research, however, public sector investment 
similar to DFID's is urgently required to tackle public health needs.

Dr. Pecoul said, "By honoring the G8 pledge to support drug research and 
development for neglected diseases, the UK government via its funding of 
DNDi and other PDPs is leading the way in accelerating the fight against 
neglected diseases.  We urge other governments to join the fight against 
these devastating diseases."



The Drugs for Neglected Diseases Initiative (DNDi) is an independent, 
not-for-profit drug development initiative established in 2003 by Médecins 
sans Frontières (MSF) along with five public sector institutions - the 
Oswaldo Cruz Foundation from Brazil, the Indian Council of Medical Research, 
the Kenya Medical Research Institute, the Ministry of Health of Malaysiam, 
and France's Pasteur Institute - and the UNICEF/UNDP/World Bank/WHO's 
Special Programme for Research and Training in Tropical Diseases (TDR) 
acting as a permanent observer to the initiative. With a current portfolio 
of 20 projects, DNDi aims to develop new, improved, and field-relevant drugs 
for neglected diseases - such as leishmaniasis, human African 
trypanosomiasis, and Chagas disease - that afflict the very poor in 
developing countries. DNDi also raises awareness about the need for greater 
R&D for neglected diseases and strengthens existing research capacity in 
disease-endemic countries. For further information, please consult 
http://www.dndi.org
###
For more information, or to arrange an interview with Dr Bernard Pecoul, 
contact Ann-Marie SEVCSIK at amsevcsik@dndi.org; +1-646-258-8131 or +41 
(0)79 814 9147) 



<Prev in Thread] Current Thread [Next in Thread>
  • [e-med] DNDi reçois 6.5 million£ du guovernementanglais pour la recherche sur les maladies négligées, Pascal Millet <=